Abstract
There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Current Pharmaceutical Design
Title: Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence
Volume: 14 Issue: 14
Author(s): K. Hatakka and M. Saxelin
Affiliation:
Keywords: Probiotics, Lactobacillus, Bifidobacterium, gastrointestinal, oral, respiratory, urogenital, infection
Abstract: There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring bodys normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Export Options
About this article
Cite this article as:
Hatakka K. and Saxelin M., Probiotics in Intestinal and Non-Intestinal Infectious Diseases – Clinical Evidence, Current Pharmaceutical Design 2008; 14 (14) . https://dx.doi.org/10.2174/138161208784480162
DOI https://dx.doi.org/10.2174/138161208784480162 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Triple-Valve Endocarditis in a Diabetic Patient: Case Report and Literature Review
Current Cardiology Reviews The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Multiple Drugs Causing Severe Anemia in Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets The Role of the Coagulase-negative Staphylococci (CoNS) in Infective Endocarditis; A Narrative Review from 2000 to 2020
Current Pharmaceutical Biotechnology Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients
Current Clinical Pharmacology Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Prediction Models and Scores in Adult Congenital Heart Disease
Current Pharmaceutical Design Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design